TriSalus Life Sciences (TLSI) Liabilities and Shareholders Equity (2020 - 2026)

TriSalus Life Sciences' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $71.0 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 147.96% year-over-year to $71.0 million in Q1 2026; TTM through Mar 2026 was $184.1 million, a 63.63% increase from a year earlier, with the FY2025 full-year figure at $35.3 million, up 47.39% from the prior year.
• Liabilities and Shareholders Equity improved to $71.0 million in Q1 2026 per TLSI's latest filing, from $35.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $251.3 million in Q3 2022 and bottomed at $12.2 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $32.4 million (2024), against an average of $69.4 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 95.12% in 2023 and soared 165.01% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $22.0 million in 2022, then increased by 11.83% to $24.6 million in 2023, then fell by 2.55% to $24.0 million in 2024, then soared by 47.39% to $35.3 million in 2025, then jumped by 100.9% to $71.0 million in 2026.
• Per Business Quant, the three latest TLSI Liabilities and Shareholders Equity figures stand at $71.0 million (Q1 2026), $35.3 million (Q4 2025), and $36.5 million (Q3 2025).